Ray Dalio
BBIO icon

Ray Dalio’s BridgeBio Pharma BBIO Stock Holding History

Ray Dalio’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.4M Buy
448,143
+188,684
+73% +$13.2M 0.14% 123
2026
Q1 		$19.3M Buy
259,459
+216,287
+501% +$15.7M 0.09% 165
2025
Q4 		$3.3M Buy
+43,172
New +$2.83M 0.01% 647

Other funds holding BBIO

Jupiter Topco
Jupiter Topco New York $245B AUM
Kohlberg Kravis Roberts & Co
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Ray Dalio's BBIO Position: Q2 2026 in Review

Ray Dalio increased its BridgeBio Pharma (BBIO) stake by 73% in Q2 2026, buying an estimated $13.2M and bringing the position to 448,143 shares worth $33.4M. The position accounts for 0.14% of the portfolio, ranked #123.

Ray Dalio first reported a position in BBIO in Q4 2025 and has held it in 3 quarters since. 476 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Ray Dalio held 448,143 shares of BridgeBio Pharma worth $33.4M as of Q2 2026.
  • Ray Dalio bought 188,684 BridgeBio Pharma shares in Q2 2026, an estimated $13.2M.
  • BridgeBio Pharma made up 0.14% of Ray Dalio's portfolio in Q2 2026, its #123 holding.
  • Ray Dalio first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 3 quarters since.
  • 476 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.